For thyroid cancer patients with elevated thyroid protein levels but no visible tumors, a single dose of radioactive iodine (5.55 GBq) is linked to a 76% chance of remaining cancer-free for five years, though about one-third still show signs of persistent disease activity.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether radioiodine adjuvant treatment for unexplained hyperthyroglobulinemia improves long-term disease-free survival compared to observation or alternative interventions across diverse populations.
A systematic review and meta-analysis of all prospective trials comparing radioiodine adjuvant therapy (5.55 GBq) versus observation or TSH suppression alone in patients with differentiated thyroid cancer and Tgoff > 10 ng/mL without structural disease, with primary outcome of 5-year disease-free survival and secondary outcomes of recurrence patterns and quality of life.
Whether 5.55 GBq radioiodine adjuvant treatment improves disease-free survival compared to no treatment in patients with unexplained hyperthyroglobulinemia.
A multicenter, double-blind, placebo-controlled trial of 400 patients with differentiated thyroid cancer and Tgoff > 10 ng/mL but no structural disease on imaging, randomized to receive 5.55 GBq radioiodine or a sham procedure, with primary endpoint of 5-year disease-free survival and mandatory annual imaging and Tg monitoring.
Whether radioiodine adjuvant treatment for unexplained hyperthyroglobulinemia independently predicts improved disease-free survival after adjusting for Tg kinetics, tumor size, and lymph node status.
A prospective cohort study of 600 patients with differentiated thyroid cancer and Tgoff > 10 ng/mL without structural disease, stratified by whether they received 5.55 GBq radioiodine or were observed, with multivariate analysis controlling for age, Tg doubling time, BRAF status, and extent of initial surgery.
Whether patients who later developed recurrence were less likely to have received radioiodine adjuvant treatment for unexplained hyperthyroglobulinemia.
A case-control study comparing 150 patients who developed structural recurrence after unexplained hyperthyroglobulinemia to 300 matched controls who remained recurrence-free, assessing prior receipt of 5.55 GBq radioiodine and timing of treatment relative to Tg rise.
The proportion of patients with unexplained hyperthyroglobulinemia who achieve biochemical remission after radioiodine adjuvant treatment at a single time point.
A cross-sectional analysis of 300 patients with differentiated thyroid cancer and Tgoff > 10 ng/mL without structural disease, measuring Tg levels and response classification (ER, IR, BIR) 12 months after receiving 5.55 GBq radioiodine.